Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DBZ87Q
|
|||
Drug Name |
BGB-A445
|
|||
Drug Type |
Antibody
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
Company |
BeiGene
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | OX40L receptor (CD134) | Target Info | . | [2] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
NetPath Pathway | IL2 Signaling Pathway | |||
Wnt Signaling Pathway | ||||
Pathway Interaction Database | Downstream signaling in naï | |||
Reactome | TNFs bind their physiological receptors |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04215978) Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of BeiGene. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.